Literature DB >> 23050510

The FDA's assessment of two drugs for chronic weight management.

Eric Colman1, Julie Golden, Mary Roberts, Amy Egan, Joyce Weaver, Curtis Rosebraugh.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 23050510     DOI： 10.1056/NEJMp1211277

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  61 in total

1.  Challenging obesity: Patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies.

Authors:  Caroline M Apovian; W Timothy Garvey; Donna H Ryan
Journal:  Obesity (Silver Spring)       Date:  2015-07       Impact factor: 5.002

2.  Potential anti-obesity effects of a long-acting cocaine hydrolase.

Authors:  Xirong Zheng; Jing Deng; Ting Zhang; Jianzhuang Yao; Fang Zheng; Chang-Guo Zhan
Journal:  Chem Biol Interact       Date:  2016-05-06       Impact factor: 5.192

3.  Serotonin 2C receptors in pro-opiomelanocortin neurons regulate energy and glucose homeostasis.

Authors:  Eric D Berglund; Chen Liu; Jong-Woo Sohn; Tiemin Liu; Mi Hwa Kim; Charlotte E Lee; Claudia R Vianna; Kevin W Williams; Yong Xu; Joel K Elmquist
Journal:  J Clin Invest       Date:  2013-11-01       Impact factor: 14.808

4.  The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation.

Authors:  Anita Chawla; Ginger Carls; Edmund Deng; Edward Tuttle
Journal:  Pharmacoeconomics       Date:  2015-07       Impact factor: 4.981

Review 5.  Obesity: Current and potential pharmacotherapeutics and targets.

Authors:  Vidya Narayanaswami; Linda P Dwoskin
Journal:  Pharmacol Ther       Date:  2016-10-20       Impact factor: 12.310

6.  Weight Loss After RYGB Is Independent of and Complementary to Serotonin 2C Receptor Signaling in Male Mice.

Authors:  Jill S Carmody; Nadia N Ahmad; Sriram Machineni; Scott Lajoie; Lee M Kaplan
Journal:  Endocrinology       Date:  2015-06-11       Impact factor: 4.736

Review 7.  Emerging combinatorial hormone therapies for the treatment of obesity and T2DM.

Authors:  Sharon A Sadry; Daniel J Drucker
Journal:  Nat Rev Endocrinol       Date:  2013-03-12       Impact factor: 43.330

8.  Directly Observable Behavioral Effects of Lorcaserin in Rats.

Authors:  Katherine M Serafine; Kenner C Rice; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2015-09-17       Impact factor: 4.030

9.  Molecular and Neural Functions of Rai1, the Causal Gene for Smith-Magenis Syndrome.

Authors:  Wei-Hsiang Huang; Casey J Guenthner; Jin Xu; Tiffany Nguyen; Lindsay A Schwarz; Alex W Wilkinson; Or Gozani; Howard Y Chang; Mehrdad Shamloo; Liqun Luo
Journal:  Neuron       Date:  2016-09-29       Impact factor: 17.173

Review 10.  Lorcaserin: a review of its use in chronic weight management.

Authors:  Sheridan M Hoy
Journal:  Drugs       Date:  2013-04       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.